Discovery of Antagonists of Phosphoinositide Signaling

Information

  • Research Project
  • 6700872
  • ApplicationId
    6700872
  • Core Project Number
    R43CA099434
  • Full Project Number
    5R43CA099434-02
  • Serial Number
    99434
  • FOA Number
    PA-01-91
  • Sub Project Id
  • Project Start Date
    2/1/2003 - 21 years ago
  • Project End Date
    7/31/2005 - 19 years ago
  • Program Officer Name
    FORRY-SCHAUDIES, SUZANNE L.
  • Budget Start Date
    2/1/2004 - 20 years ago
  • Budget End Date
    7/31/2005 - 19 years ago
  • Fiscal Year
    2004
  • Support Year
    2
  • Suffix
  • Award Notice Date
    2/11/2004 - 20 years ago

Discovery of Antagonists of Phosphoinositide Signaling

[unreadable] DESCRIPTION (provided by applicant): [unreadable] Phosphoinositides are key lipid second messengers in many cellular signaling processes. In particular, the activity of phosphatidylinositol 3-kinase (PI 3-K), and the synthesis of its lipid products, is important in pathways mediating cell proliferation, survival, and motility. Alterations in PI 3-K mediated signaling are common to many cancers. Targeting PI 3-K activity is recognized as a potential anti-cancer strategy. The lipid products of PI 3-K act as second messengers by activating downstream protein effectors by their recruitment to specific domains in the plasma membrane. We propose a new strategy for inhibiting PI 3-K mediated signaling in disease by preventing the interaction of PI(3,4,5)P3 with these protein effectors. In vitro and cell-based assays will be developed to determine the interaction of selected effectors with PI(3,4,5)P3. These will be used to identify compounds which block the interaction of PI(3,4,5)P3 with effector proteins using libraries of synthetic small molecules and of compounds from natural sources. The mode of action of inhibitors will also be explored in cell culture. Identification and characterization of novel antagonists of PI 3-K signaling may lead to new therapies for cancer, inflammation, and diabetes. [unreadable] [unreadable]

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    250000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:250000\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ECHELON BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    84108
  • Organization District
    UNITED STATES